With 137 patents held between 2002 and 2022, Bristol-Myers Squibb Co holds the most number of Nanomedicine patents in the Healthcare sector in the Europe region, of which 66.4% was contributed by Abraxis BioScience, LLC.
The second largest number of patents were held by Pfizer Inc with 109 Nanomedicine patents. The third largest number of patents were held by Merck & Co Inc with 49 Nanomedicine patents, of which 53.1% was contributed by Schering Aktiengesellschaft. The fourth largest number of patents were held by F. Hoffmann-La Roche Ltd with 45 Nanomedicine patents, of which 33.3% was contributed by Genentech USA Inc. The fifth largest number of patents were held by Gilead Sciences Inc with 45 Nanomedicine patents, of which 57.8% was contributed by Immunomedics Inc.
The top five patents holders, i.e., Bristol-Myers Squibb Co, Pfizer Inc, Merck & Co Inc, F. Hoffmann-La Roche Ltd, and Gilead Sciences Inc, together held 385 Nanomedicine patents during the period.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
United States of America
United States of America
Japan
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer